JP2007516218A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516218A5
JP2007516218A5 JP2006528067A JP2006528067A JP2007516218A5 JP 2007516218 A5 JP2007516218 A5 JP 2007516218A5 JP 2006528067 A JP2006528067 A JP 2006528067A JP 2006528067 A JP2006528067 A JP 2006528067A JP 2007516218 A5 JP2007516218 A5 JP 2007516218A5
Authority
JP
Japan
Prior art keywords
methoxy
pharmaceutical composition
methyl
composition according
phenylisoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006528067A
Other languages
English (en)
Japanese (ja)
Other versions
JP4718467B2 (ja
JP2007516218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/030431 external-priority patent/WO2005030791A2/en
Publication of JP2007516218A publication Critical patent/JP2007516218A/ja
Publication of JP2007516218A5 publication Critical patent/JP2007516218A5/ja
Application granted granted Critical
Publication of JP4718467B2 publication Critical patent/JP4718467B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006528067A 2003-09-23 2004-09-17 イソキノリノンカリウムチャネル阻害剤 Expired - Fee Related JP4718467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50510103P 2003-09-23 2003-09-23
US60/505,101 2003-09-23
PCT/US2004/030431 WO2005030791A2 (en) 2003-09-23 2004-09-17 Isoquinolinone potassium channel inhibitors

Publications (3)

Publication Number Publication Date
JP2007516218A JP2007516218A (ja) 2007-06-21
JP2007516218A5 true JP2007516218A5 (enExample) 2007-08-02
JP4718467B2 JP4718467B2 (ja) 2011-07-06

Family

ID=34392976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006528067A Expired - Fee Related JP4718467B2 (ja) 2003-09-23 2004-09-17 イソキノリノンカリウムチャネル阻害剤

Country Status (7)

Country Link
US (2) US7723352B2 (enExample)
EP (1) EP1667982B1 (enExample)
JP (1) JP4718467B2 (enExample)
CN (1) CN1856476A (enExample)
AU (1) AU2004276236B2 (enExample)
CA (1) CA2539814C (enExample)
WO (1) WO2005030791A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667978B1 (en) * 2003-09-23 2013-09-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
WO2005030726A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
AU2004276236B2 (en) * 2003-09-23 2008-01-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
WO2005030727A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US7763614B2 (en) * 2003-09-23 2010-07-27 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
AU2005267884B2 (en) 2004-07-29 2011-04-21 Merck Sharp & Dohme Corp. Potassium channel inhibitors
DE102005028862A1 (de) * 2005-06-22 2007-01-11 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
ES2331853T3 (es) 2005-06-28 2010-01-18 Sanofi-Aventis Derivados de isoquinolina como inhibidores de rho-cinasa.
ES2372067T3 (es) 2005-07-26 2012-01-13 Sanofi Derivados de ciclohexilamina isoquinolona como inhibidores de la rho-quinasa.
NZ565668A (en) 2005-07-26 2010-09-30 Sanofi Aventis Piperidinyl-substituted isoquinolone derivatives as RHO-kinase inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
JP2009527493A (ja) * 2006-02-17 2009-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カリウムチャンネル開放物質としてのピラゾリルキナゾリノン
KR101517154B1 (ko) 2006-12-27 2015-04-30 사노피 Rho-키나제의 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
HRP20100705T1 (hr) 2006-12-27 2011-01-31 Sanofi-Aventis Cikloalkilaminski supstituirani izokinolinski i izokinolinonski derivati
ATE502027T1 (de) 2006-12-27 2011-04-15 Sanofi Aventis Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
CN101595094B (zh) 2006-12-27 2013-02-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮衍生物
RU2009128693A (ru) 2006-12-27 2011-02-10 Санофи-Авентис (Fr) Замещенные производные изохинолина и изохинолинона
MY148514A (en) * 2006-12-27 2013-04-30 Sanofi Aventis Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
CA2673920C (en) * 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
BRPI0806371A2 (pt) 2007-01-22 2011-09-13 Gtx Inc agentes ligação de receptor nuclear
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
AU2009262509B2 (en) 2008-06-24 2014-01-30 Sanofi Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as Rho kinase inhibitors
AU2009262517B2 (en) 2008-06-24 2014-01-09 Sanofi Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors
ES2436531T3 (es) 2008-06-24 2014-01-02 Sanofi Isoquinolinas e isoquinolinonas sustituidas en posición 6
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2680872B1 (en) 2011-03-02 2018-08-15 BioIncept LLC Use of pif peptides for treating infections, atherosclerosis and peritonitis
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
PE20161065A1 (es) 2013-10-18 2016-11-19 Celgene Quanticel Res Inc Inhibidores de bromodominio
EA038715B1 (ru) * 2014-01-24 2021-10-08 Селджен Квонтисел Рисёрч, Инк. Ингибиторы бромодомена
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CA2996874A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Compositions and methods for the treatment of neurodamage
EP3341739A4 (en) 2015-08-28 2019-07-10 BioIncept LLC MUTATED PEPTIDES AND METHOD FOR TREATING SUBJECTS THEREWITH
JP2019513804A (ja) 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ,インク. 治療用化合物
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2021203028A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594380A (en) 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
US3878215A (en) 1971-12-01 1975-04-15 Sandoz Ag 2-Alkyl-3-substituted-4-aryl isoquinolines
US4897391A (en) 1988-06-17 1990-01-30 Schering Corporation Tricyclic anti-allergy, antiinflammatory and anti-hyperproliferative compounds
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
US5728712A (en) 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU2002212969B2 (en) * 2000-09-20 2006-07-06 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
WO2002094790A1 (en) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
US7402595B2 (en) 2002-02-13 2008-07-22 Takeda Pharmaceutical Company Limited JNK inhibitor
AU2004276236B2 (en) * 2003-09-23 2008-01-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
WO2005030727A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US7763614B2 (en) * 2003-09-23 2010-07-27 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
EP1667978B1 (en) * 2003-09-23 2013-09-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
WO2005030726A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors

Similar Documents

Publication Publication Date Title
JP2007516218A5 (enExample)
JP2007506748A5 (enExample)
JP2007506742A5 (enExample)
CA2539814A1 (en) Isoquinolinone potassium channel inhibitors
EP1246805A1 (en) 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
WO2001032625A1 (en) Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
JP2009120619A (ja) 心不全の予防又は治療のための医薬組成物
AU2008274201A1 (en) Compounds and methods for modulating Rho GTPases
Rowland et al. The Comparativee Effects of Diltiazem and Verapamil on Atrioventricular Conduction and Atrioventricular Reentry Tachycardia
Fiala et al. Termination of long‐lasting persistent versus short‐lasting persistent and paroxysmal atrial fibrillation by ablation
US20090215745A1 (en) Association of a sinus node If current inhibitor and a calcium inhibitor, and pharmaceutical compositions containing it
JP2007527904A5 (enExample)
ES2296964T3 (es) Compuestos a base de nitrato organico para el tratamiento de ateroesclerosis y enfermedades vasculares.
US7163949B1 (en) 4-phenyl substituted tetrahydroisoquinolines and use thereof
Aizawa et al. Conductive property of the zone of slow conduction of reentrant ventricular tachycardia and its relation to pacing induced terminability
CA2766533A1 (en) Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients
US6110927A (en) Loratadine for use as an antiarrhythmic
JP2934323B2 (ja) 抗血栓性化合物
Menezes Júnior et al. Management of an Electrical Storm: Definitions, Mechanisms, Diagnosis, and Treatment Strategies
JP2008516952A5 (enExample)
MY138896A (en) Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
Wijffels et al. Non-invasive characteristics of atrial fibrillation: the value of Holter recordings for the treatment of AF
JP2008524228A5 (enExample)
Garg et al. Atrial flutter
Kołodziej et al. Case report Brugada syndrome–underestimated cause of sudden cardiac death in patients without an organic cardiac disease–a case report